United States Biotechnology & Medical Research

Contineum Therapeutics Inc (CTNM)

Track

Over the past 90 days, Contineum Therapeutics Inc. insiders have executed 18 transactions, all of which were sales totaling approximately $2.14 million. Key executives, including the CEO and Chief Scientific Officer, conducted these planned and proposed divestments. These activities follow the company's May 2026 earnings report, during which the firm outperformed earnings expectations.
Ticker: CTNM Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Planned sale 3 Aug 2026
Value US$2,582,874.60 | Price 31.10 | Shares 48,324 (+17.7%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-03 2026-08-03 PlS Planned sale
Stengone Carmine N.

CEO and President

Executive Director
48,324 +17.7%
31.10
US$2,582,875 		48,324 +17.7% 31.10 US$2,582,875
2026-08-03 2026-08-03 PrS Proposed sale
CARMINE STENGONE

Director; Officer

Executive Director
96,674
17.91
US$428,797 		96,674 17.91 US$428,797
2026-08-03 2026-08-03 PrS Proposed sale
Daniel Lorrain

Officer

Officer
19,877
291.55
US$1,312,584 		19,877 291.55 US$1,312,584
2026-07-10 2026-07-09 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
25 -0.0%
16.00
US$400 		25 -0.0% 16.00 US$400
2026-07-10 2026-07-08 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
1,015 -0.7%
16.00
US$16,240 		1,015 -0.7% 16.00 US$16,240
2026-07-08 2026-07-08 PlS Planned sale
Stengone Carmine N.

CEO and President

Executive Director
2,500 -12.7%
16.00
US$40,000 		2,500 -12.7% 16.00 US$40,000
2026-07-08 2026-07-08 PrS Proposed sale
CARMINE STENGONE

Director; Officer

Executive Director
2,500
14.56
US$36,400 		2,500 14.56 US$36,400
2026-07-02 2026-07-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
2,501 -1.8%
16.24
US$40,608 		2,501 -1.8% 16.24 US$40,608
2026-07-02 2026-07-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
5,852 -4.1%
15.67
US$91,682 		5,852 -4.1% 15.67 US$91,682
2026-07-01 2026-07-01 PrS Proposed sale
Daniel Lorrain

Officer

Officer
9,520
16.39
US$156,033 		9,520 16.39 US$156,033
2026-07-02 2026-06-30 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
28,826 -17.1%
16.04
US$462,288 		28,826 -17.1% 16.04 US$462,288
2026-07-01 2026-06-30 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
10,833 -54.7%
16.02
US$173,590 		10,833 -54.7% 16.02 US$173,590
2026-07-01 2026-06-30 PlS Planned sale
Stengone Carmine N.

CEO and President

Executive Director
10,000 -36.7%
16.01
US$160,080 		10,000 -36.7% 16.01 US$160,080
2026-06-30 2026-06-30 PrS Proposed sale
Daniel Lorrain

Officer

Officer
28,826
15.00
US$432,390 		28,826 15.00 US$432,390
2026-06-30 2026-06-30 PrS Proposed sale
CARMINE STENGONE

Director; Officer

Executive Director
10,000
15.00
US$150,000 		10,000 15.00 US$150,000
2026-06-30 2026-06-30 PrS Proposed sale
TIMOTHY WATKINS

Officer

Officer
10,833
15.00
US$162,495 		10,833 15.00 US$162,495
2026-06-01 2026-06-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,170 -2.9%
13.16
US$54,862 		4,170 -2.9% 13.16 US$54,862
2026-06-01 2026-06-01 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
13.49
US$56,253 		4,170 13.49 US$56,253
2026-05-01 2026-05-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
300 -0.2%
13.84
US$4,152 		300 -0.2% 13.84 US$4,152
2026-05-01 2026-05-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
3,870 -2.6%
13.06
US$50,542 		3,870 -2.6% 13.06 US$50,542
2026-05-01 2026-05-01 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
12.82
US$53,459 		4,170 12.82 US$53,459
2026-04-06 2026-04-06 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,170 -2.7%
13.43
US$56,014 		4,170 -2.7% 13.43 US$56,014
2026-04-06 2026-04-06 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
914
13.44
US$12,284 		914 13.44 US$12,284
2026-03-02 2026-03-02 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
3,611 -100.0%
15.02
US$54,220 		3,611 -100.0% 15.02 US$54,220
2026-03-02 2026-03-02 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,170 -2.7%
15.01
US$62,585 		4,170 -2.7% 15.01 US$62,585
2026-02-26 2026-02-25 PlS Planned sale
Stengone Carmine N.

CEO and President

Executive Director
2,700 -15.3%
16.02
US$43,242 		2,700 -15.3% 16.02 US$43,242
2026-02-26 2026-02-25 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
3,824 -2.4%
16.01
US$61,228 		3,824 -2.4% 16.01 US$61,228
2026-02-26 2026-02-24 PlS Planned sale
Stengone Carmine N.

CEO and President

Executive Director
4,400 -22.7%
16.02
US$70,486 		4,400 -22.7% 16.02 US$70,486
2026-02-26 2026-02-24 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,300 -2.7%
16.03
US$68,936 		4,300 -2.7% 16.03 US$68,936
2026-02-20 2026-02-19 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
100 -0.1%
16.00
US$1,600 		100 -0.1% 16.00 US$1,600
2026-02-13 2026-02-11 PlS Planned sale
Stengone Carmine N.

CEO and President

Executive Director
400 -2.6%
16.00
US$6,400 		400 -2.6% 16.00 US$6,400
2026-02-13 2026-02-11 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
400 -0.3%
16.00
US$6,400 		400 -0.3% 16.00 US$6,400
2026-02-11 2026-02-11 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
16,050
15.75
US$252,788 		16,050 15.75 US$252,788
2026-02-11 2026-02-11 PrS Proposed sale
CARMINE STENGONE

Director; Officer

Executive Director
7,500
15.75
US$118,125 		7,500 15.75 US$118,125
2026-02-05 2026-02-03 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
1,170 -0.7%
15.25
US$17,837 		1,170 -0.7% 15.25 US$17,837
2026-02-05 2026-02-03 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
3,000 -1.9%
14.82
US$44,469 		3,000 -1.9% 14.82 US$44,469
2026-02-03 2026-02-03 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
14.38
US$59,965 		4,170 14.38 US$59,965
2026-01-30 2026-01-28 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
811 -100.0%
14.48
US$11,747 		811 -100.0% 14.48 US$11,747
2026-01-30 2026-01-28 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
2,800 -77.5%
14.09
US$39,441 		2,800 -77.5% 14.09 US$39,441
2026-01-06 2026-01-05 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
500 -0.3%
11.13
US$5,565 		500 -0.3% 11.13 US$5,565
2026-01-06 2026-01-05 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
3,670 -2.2%
10.35
US$37,978 		3,670 -2.2% 10.35 US$37,978
2026-01-05 2026-01-05 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
11.39
US$47,496 		4,170 11.39 US$47,496
2025-12-30 2025-12-29 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
3,611 -100.0%
12.06
US$43,558 		3,611 -100.0% 12.06 US$43,558
2025-12-29 2025-12-29 PrS Proposed sale
TIMOTHY WATKINS

Officer

Officer
10,833
12.41
US$134,438 		10,833 12.41 US$134,438
2025-12-30 2025-12-23 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,170 -2.5%
12.23
US$51,009 		4,170 -2.5% 12.23 US$51,009
2025-12-23 2025-12-23 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
12.26
US$51,124 		4,170 12.26 US$51,124
2024-11-27 2024-11-25 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
1,010 -0.6%
16.02
US$16,177 		1,010 -0.6% 16.02 US$16,177
2024-11-20 2024-11-18 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
99 -0.1%
17.05
US$1,688 		99 -0.1% 17.05 US$1,688
2024-11-20 2024-11-18 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
6,091 -3.5%
16.37
US$99,733 		6,091 -3.5% 16.37 US$99,733
2024-11-18 2024-11-18 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
26,370
17.21
US$453,828 		26,370 17.21 US$453,828
Explore more

More insider trading research around Contineum Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America